Pierfranco Conte, MD, discusses the findings of the OlympiAD trial in BRCA-mutated HER2-negative metastatic breast cancer.
Pierfranco Conte, MD, Department of Surgery, Oncology and Gastroenterology, Istituto Oncologico Veneto, discusses the findings of the OlympiAD trial in BRCA-mutated HER2-negative metastatic breast cancer.
Patients in the OlympiAD trial were randomized to receive the PARP inhibitor olaparib (Lynparza) or physician’s choice of chemotherapy. When the study was published a few years ago, the olaparib arm had improved progression-free survival, response rate, and quality of life compared with chemotherapy, explains Conte.
In the updated analysis at the 2019 San Antonio Breast Cancer Symposium, the median overall survival was 19.3 months with olaparib versus 17.1 months with chemotherapy (HR, 0.84; 95% CI, 0.63-1.12). The 4-year OS rates were 18.9% compared with 14.2%, respectively.